* Affymetrix Inc., of Santa Clara, Calif., has added American Home Products Corp. (AHP), of Madison, N.J., as an EasyAccess customer. AHP exercised an option to join its wholly owned subsidiary Genetics Institute in the program, which provides access to Affymetrix's custom and standard GeneChip expression monitoring probe arrays, instrumentation and software.
* Becton Dickinson and Co., of Franklin Lakes, N.J., plans to integrate three existing businesses to form a single worldwide bioscience/diagnostic business. The integration will bring together Baltimore-based Becton Dickinson Microbiology Systems; Becton Dickinson Immunocytometry Systems, of San Jose, Calif.; and Becton Dickinson Labware, of Franklin Lakes. The consolidation takes effect Jan. 1, 1999, with the as yet unnamed business to be headquartered in San Jose.
* Collateral Therapeutics Inc., of San Diego, terminated a license agreement with AMRAD Development Pty. Ltd., of Victoria, Australia, and The Ludwig Institute for Cancer Research, of New York, covering the use of certain genes for vascular endothelial growth factor. Collateral said its "large portfolio of angiogenic genes are more than sufficient to conduct further research and development for all of its currently envisioned non-surgical cardiovascular gene therapy products." The agreement was signed in March 1997.
* Immunex Corp., of Seattle, reported positive results from the second segment of an Enbrel study in children and teen-agers suffering from juvenile rheumatoid arthritis. Patients receiving the drug experienced less pain and swelling in their joints and decreased disease activity. Currently under review for marketing at the FDA, Enbrel is a recombinant version of the soluble p75 TNF receptor linked to the Fc portion of human IgG1.
* Nymox Pharmaceutical Corp., of Rockville, Md., has developed a new antibacterial for fighting all strains of E. coli 0157, implicated in so-called "hamburger disease." The product, NXC4720, appears to be nontoxic in animals, with a good stability profile and a useful host range, Nymox said. NXC4720 is targeted for industrial testing in the next six to 12 months.